Trial Profile

Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary)
Indications Adult-onset Still's disease
Focus Therapeutic Use
Acronyms CONSIDER

Most Recent Events

06 Jun 2020 Results of 24 weeks treatment presented at the 21st Annual Congress of the European League Against Rheumatism.
13 May 2020 Primary endpoint (Efficacy of canakinumab with a clinically-significant reduction in disease activity) has not been met as per results published in the Annals of the Rheumatic Diseases
13 May 2020 Results published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com